Thyroid safety in patients treated with liraglutide

Journal of Endocrinological Investigation

Volumn 36, Issue 2, 2013, Pages 140-145

  Gallo, M ^a  

^a City of Health and Science Torino   (Italy)

Author keywords

Liraglutide; Medullary thyroid cancer; Safety; Thyroid cancer; Type 2 diabetes

Indexed keywords

CALCITONIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; PARATHYROID HORMONE; PLACEBO;

CALCITONIN BLOOD LEVEL; CELL HYPERPLASIA; CELL PROLIFERATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEMATOPOIETIC CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; L CELL; LONG TERM SURVIVAL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID TUMOR;

EID: 84876208039     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346749     Document Type: Review

References (44)

1. Kieffer TJ, Habener JL. The glucagon-like peptides. Endocr Rev 1999, 20: 876-913.
2. Drucker DJ. The biology of incretin hormones. Cell Metab 2006, 3: 153-65.
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87: 1409-39.
4. Novo Nordisk. Liraglutide (injection) for the treatment of patients with type 2 diabetes. NDA 22-341. Briefing document. Endocrine and Metabolic Drug Advisory Committee, 2 April 2009. http://www.fda.gov/downloads/ advisorycommittees/committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm148659.pdf. Accessed January 4, 2012.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient- centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35: 1364-79.
6. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American College of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes: an algorithm for glycemic control. Endocr Pract 2009, 15: 540-59.
7. Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli A; Associazione Medici Diabetologi. Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach. Diabetes Technol Ther 2012, 14: 373-8.
8. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010, 14: 1-248.
9. Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin 2011, 27: 897-906.
10. Shyangdan D, Cummins E, Royle P, Waugh N. Liraglutide for the treatment of type 2 diabetes. Health Technol Assess 2011, 15 (Suppl 1): 77-86.
11. Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med 2012, 29: 313-20.
12. McGill JB. Insights from the Liraglutide Clinical Development Program-the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009, 121: 16-25.
13. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160: 909-17.
14. Astrup A, Rössner S, Van Gaal L, et al; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374: 1606-16.
15. stScientific Sessions, San Diego, CA, 2011 (abstract).
16. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide- 1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011: 215764.
17. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151: 1473-86.
18. Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002, 110: 1849-57.
19. WangW, Lewin E, Olgaard K. Role of calcitonin in the rapid minuteto- minute regulation of plasma Ca2+ homeostasis in the rat. Eur J Clin Invest 2002, 32: 674-81.
20. Persson P, Grunditz T, Axelson J, Sundler F, Häkanson R. Cholecystokinins but not gastrin-17 release calcitonin from thyroid Ccells in the rat. Regul Pept 1988, 21: 45-56.
21. Vitale G, Ciccarelli A, Caraglia M, et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin Chem 2002, 48: 1505-10.
22. Kurosawa M, Sato A, Shiraki M, Takahashi Y. Secretion of calcitonin from the thyroid gland increases in aged rats. Arch Gerontol Geriatr 1988, 7: 229-38.
23. O'Toole K, Fenoglio-Preiser C, Pushparaj N. Endocrine changes associated with the human aging process: III. Effect of age on the number of calcitonin immunoreactive cells in the thyroid gland. Hum Pathol 1985, 16: 991-1000.
24. Hirsch PF, Baruch H. Is calcitonin an important physiological substance? Endocrine 2003, 21: 201-8.
25. Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer 2010, 9: 449-57.
26. Wolfe HJ, Delellis RA. Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab 1981, 10: 351-65.
27. LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997, 82: 39-41.
28. Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments. Curr Opin Oncol 2010, 23: 22-7.
29. Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008, 22: 941-53.
30. d'Herbomez M, Caron P, Bauters C, et al; French Group GTE (Groupe des Tumeurs Endocrines). Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007, 157: 749-55.
31. Bydureon (exenatide) Product Information. 17/06/2011 Bydureon -EMEA/H/C/002020. Summary of Product Characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002020/WC500108241. pdf. Accessed January 4, 2012.
32. Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012, 153: 1538-47.
33. Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP- 1 and Ct concentration in humans: lack of evidence of Ct release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP- 1 analog, liraglutide. J Clin Endocrinol Metab 2011, 96: 853-60.
34. Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005, 90: 2029-34.
35. Guyétant S, Rousselet MC, Durigon M, et al. Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 1997, 82: 42-7.
36. Sosa JA, Udelsman R. Papillary thyroid cancer. Surg Oncol Clin N Am 2006, 15: 585-601.
37. Yeomans ND. Omeprazole: short- and long-term safety. Adverse Drug React Toxicol Rev 1994, 13: 145-56.
38. Thurston V, Williams ED. Experimental induction of C cell tumours in thyroid by increased dietary content of vitamin D3. Acta Endocrinol (Copenh) 1982, 100: 41-5.
39. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide- -the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362: 774-7.
40. Important drug warning concerning Victoza®. Subject: potential risks of thyroid C-cell tumours and acute pancreatitis associated with Victoza®. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/UCM258828.pdf. Accessed January 4, 2012.
41. Gier B, Butler PC, Lai CK, Kirakossian D, Denicola MM, Yeh MW. Glucagon like Peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012, 97: 121-31.
42. Waser B, Beetschen K, Pellegata NS, Reubi JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 2011, 94: 291-301.
43. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375: 2234-43.
44. Gallo M, Esposito K, Giugliano D. Diabetes medications and cancer: A way out of uncertainty. Diab Res Clin Pract 2012, 97: 175-7.